Compare Cytokinetics Inc (CYTK) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Sezzle Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Sezzle Inc trades at $126.02 (market cap $4.32B). The key difference: Cytokinetics Inc is far larger — about 2.5× Sezzle Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | SEZL | |
|---|---|---|
Market Cap | $10.63B | $4.32B |
Sector | Technology | Technology |
52-Week High | $87.26 | $188.55 |
52-Week Low | $35.33 | $50.97 |
Enterprise Value | $10.74B | $4.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $75.64, down 2.39% on the day, amid a bearish technical signal despite a Q2 2026 earnings beat. The stock shows negative profitability with a net income margin of -1,321.12% and a high P/S ratio of 140.65, reflecting significant losses and premium valuation relative to sales. Recent news highlights strong uptake of MYQORZO and UK regulatory approval, supporting commercial momentum.
The outlook is polarized: analyst consensus is strongly bullish with a $111.14 price target, but high cash burn and competitive pressures pose risks. Investment opportunity hinges on MYQORZO's market expansion, while execution and funding needs remain key challenges for shareholders.
Sezzle (SEZL) trades at $125.44, up 6.31% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 30.35% net income margin and consistent earnings beats. Recent Q2 2026 results showed revenue growth of 51.7% year-over-year to $149.7 million, with management raising full-year guidance for the third time in 2026, indicating robust operational momentum despite a recent stock decline.
The outlook is mixed: bullish fundamentals and analyst consensus support upside to a $158.29 price target, but technical indicators and valuation premiums pose risks. Key opportunities include subscriber growth and AI integration, while risks involve execution pressure and market volatility. Investors should weigh strong profitability against high P/E and P/S ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
